Enzolytics Inc. and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibody Therapies

COLLEGE STATION, Texas and INCHEON, South Korea: Enzolytics Inc. to leverage Samsung Biologics' development and manufacturing expertise to advance both Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibody Therapies to IND. Samsung Biologics to offer a seamless, end-to-end CDMO service with support from its San Francisco R&D Center. COLLEGE STATION, Texas and INCHEON,...

Click to view original post